Emergent BioSolutions Inc.
EBS
$5.08
$0.265.39%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 50.10% | 4.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 50.10% | 4.98% | |||
| Cost of Revenue | 18.08% | -12.34% | |||
| Gross Profit | 85.89% | 34.73% | |||
| SG&A Expenses | -4.29% | -24.35% | |||
| Depreciation & Amortization | 4.24% | 1.23% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.40% | -15.06% | |||
| Operating Income | 526.42% | 146.90% | |||
| Income Before Tax | -1,341.04% | 126.43% | |||
| Income Tax Expenses | 110.61% | 69.23% | |||
| Earnings from Continuing Operations | -2,750.00% | 112.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,750.00% | 112.45% | |||
| EBIT | 526.42% | 146.90% | |||
| EBITDA | 168.36% | 33,600.00% | |||
| EPS Basic | -2,765.80% | 112.57% | |||
| Normalized Basic EPS | 320.11% | 130.03% | |||
| EPS Diluted | -4,800.13% | 107.13% | |||
| Normalized Diluted EPS | 357.54% | 127.57% | |||
| Average Basic Shares Outstanding | -0.58% | -0.95% | |||
| Average Diluted Shares Outstanding | -8.67% | 7.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||